We retrospectively analyzed the relationship between busulfan average steady-state plasma concentration (C SS ) and graft rejection in 53 children receiving busulfan/cyclophosphamide (BU/CY) preparative regimens prior to hematopoietic stem cell transplantation (HSCT). Patients received a total oral busulfan dose of 11 to 28 mg/kg followed by a total cyclophosphamide dose of 120 to 335 mg/kg in preparation for allogeneic grafts (HLA-matched or HLA partially matched sibling, parent or unrelated donor). Graft rejection occurred in eight (15%) patients. Busulfan C SS (P = 0.0024) was the only statistically significant predictor of rejection on univariate logistic regression analysis, with the risk of rejection decreasing with an increase in busulfan C SS . Severe (grade 3 or 4) regimen-related toxicity (RRT) occurred in four patients. Ten patients (19%) had a busulfan C SS higher than 900 ng/ml, one of whom had severe RRT. Higher and variable doses of cyclophosphamide may explain the lack of a relationship between busulfan C SS and RRT in children. It may be possible to improve the outcome of HSCT in pediatric patients receiving the BU/CY regimen through optimization of busulfan C SS and better definition of the contribution of activated cyclophosphamide metabolites to toxicity. phamide was later decreased to 120 mg/kg for adults to diminish regimen-related toxicity. 7 Achieving consistent engraftment has been a greater challenge in children and the dose of cyclophosphamide in general has remained at 200 mg/kg.
It is now well established that children treated with highdose busulfan, based on either a mg/kg or a mg/m 2 basis, achieve lower plasma concentrations, measured as area under the plasma-concentration time curve (AUC) or steady-state concentration (C ss , which is AUC/dosing interval) than adults. [9] [10] [11] [12] [13] [14] [15] Children below the age of 4 years are most at risk of having low busulfan plasma concentrations. The lower plasma levels of busulfan are apparently due to an enhanced ability to metabolize the drug through an upregulation of busulfan-glutathione conjugase (glutathione Stransferase A1-1). 16, 17 We 15 and others 18 have observed a relationship between low busulfan C ss and the incidence of graft rejection in patients receiving BU/CY. In a population of 15 adults (Ͼ18 years ) and 28 children (0.6-16 years) receiving BU/CY, there was a difference in the busulfan C ss needed to retain HLA-matched sibling grafts (Ͼ200 ng/ml) in comparison to that needed for partially matched related or matched unrelated donor grafts (Ͼ600 ng/ml). 15 Bolinger et al 18 did not observe a difference in threshold busulfan C ss between the different graft sources in 31 children receiving BU/CY Ϯ ATG, although few patients received grafts from partially matched related or matched unrelated donors (n = 6). 18 However, a busulfan C ss Ͻ600 ng/ml was correlated with rejection. 18 Further definition of the relationship between busulfan C ss and graft rejection in children should lead to the development of more effective conditioning regimens with a lower incidence of graft rejection.
This retrospective data analysis was undertaken to identify the relationship between busulfan C ss and graft rejection in children. The relationship between busulfan C ss and regimen-related toxicity (RRT), which has been found in adults, 19, 20 could not be assessed due to the low incidence of severe RRT in these patients.
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Methods
Patients
Records collected as part of routine clinical busulfan monitoring between April 1991 and September 1998 at the Fred Hutchinson Cancer Research Center were examined retrospectively. Inclusion required that the patients were less than 18 years old, were receiving a preparative regimen containing busulfan and cyclophosphamide, had not received a previous hematopoietic stem cell transplant and were enrolled in treatment protocols that stipulated busulfan monitoring. These patients represent approximately 52% of the pediatric patients treated with a preparative regimen including both busulfan and cyclophosphamide during that time period. Records were examined for age, gender of recipient and donor, disease, prior chemotherapy, donorrecipient HLA matching, height, weight, body surface area, preparative regimen, donor cell source and dose, medications used and toxicity up to day 28, and rejection and relapse to day of last follow-up. Patients or their guardians provided informed consent for the pharmacokinetic analysis.
The final database contained information on 53 patients, 17 of whom were included in an earlier report. 15 Patient pre-transplant demographics are described in Table 1 . The median age was 6 years (range 0.25-16), with 21 patients (39%) Ͻ4 years of age. Fifty-one percent of the patients were male. Forty-two percent of the patients had received chemotherapy weeks to months prior to administration of the preparative regimen for HSCT. Patients received busulfan every 6 h for a total of 16 doses, for a total oral busulfan dose of 11-28 mg/kg. The oral busulfan dose was less than 16 mg/kg in four patients, 30 received 16 mg/kg and 19 received greater than 16 mg/kg. In very young children unable to co-operate with oral administration of busulfan, a nasogastric tube was inserted for the administration of Table 2 . Cyclophosphamide was administered after busulfan as part of their transplant preparative regimen. The total dose of cyclophosphamide varied from 120 to 335 mg/kg depending on disease and the treatment protocols in which a patient was enrolled. Ten (19%) of the children received cyclophosphamide 120 mg/kg, 35 (66%) received 200 mg/kg and the eight remaining patients (15%) received Ͼ200 mg/kg. Nine (17%) patients received antithymocyte globulin (ATG) as part of the preparative regimen. The target population for the different dose levels of busulfan and cyclophosphamide are listed in Table 3 . No other antineoplastic agents or irradiation were given immediately before or concomitantly with busulfan. Forty-two percent of patients received phenytoin for seizure prophylaxis.
Bone marrow was used in 50 patients, with two patients receiving peripheral blood stem cells and one cord blood stem cells. The median cell dose from allogeneic bone marrow donors was 4.21 ϫ 10 8 /kg, with a range of 1.53 ϫ 10 8 to 2.15 ϫ 10 9 cells/kg. Twenty-six children received a graft from an HLA-matched sibling. The remaining 27 patients received grafts from HLA-matched unrelated (n = 12), partially HLA-matched parent (n = 5), partially HLA-matched unrelated donor (n = 5), HLA-matched parent (n = 3) and HLA partially matched sibling (n = 2). Using serologic methods, 11 of these 27 donor-recipient pairs were mismatched at the A, B, or C class I antigens. Of the remaining 16 donor-recipient pairs, 14 were matched at the A, B and C class I antigens and two pairs were HLA-matched at the A, B antigens. DNA sequencing of the HLA-A, B, and C genes could not be performed for 15 of the 16 serologically matched pairs because donor and/or recipient cells or DNA were not available. 21 Three of these 16 donor-recipient pairs were serologically mismatched at the DRB1.
Dosing and pharmacokinetic methods for oral busulfan
Blood samples were collected immediately before and 60, 120, 180, 240 and 360 min after the fifth and ninth doses of busulfan. Plasma busulfan concentrations were determined by gas chromatography with mass spectrometry detec- tion as previously described. 15, 22 The samples are assayed immediately to calculate busulfan C ss . The AUC is determined by summation of successive trapezoids with extrapolation using apparent elimination half-life determined by regression of the log-transformed, first-order decline data. The busulfan C ss is calculated by dividing the AUC by the dosing interval. 15, 22 A busulfan AUC of 875 m-min is equivalent to a busulfan C ss of 600 ng/ml, assuming a 6 h dosing interval. The busulfan C ss after each of these two doses was determined and the average of the two values was used in the outcome analyses. The C ss after the fifth dose could not be determined in 3/53 (5%) patients and, in those cases, the C ss after the ninth dose only was used. The busulfan C ss was obtained after the ninth dose in all patients.
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Assessment of rejection and toxicity
All patient medical charts submitted from referring physicians and from research data files were reviewed to the day of last follow-up. Median follow up was 542 days (range 15-3092 days) with date of last clinic visit or correspondence from patient, second transplant or death recorded as last follow-up. Post-transplant donor engraftment was determined by the presence of progressively rising neutrophil counts after the post-transplant nadir and bone marrow examination. When appropriate, additional evidence of engraftment was determined by in situ hybridization studies and/or HLA serological typing and/or DNA chimerism studies. Graft rejection was defined as failure of donor engraftment accompanied by return of host lymphocytes. Patients had bone marrow samples examined on days 28, 80 and 365 post transplant. Other samples were collected at other times based on clinical indication.
Regimen-related toxicity (RRT) was evaluated as described by Bearman et al. 23 All charts were reviewed (by JSM, grade 4 confirmed by JES) and the overall grade assigned was the maximum RRT grade for cardiac, bladder, renal, pulmonary, hepatic, central nervous system, mucositis, and gastrointestinal during the first 28 days after transplant.
Statistical analysis
All statistical analyses were performed using SPSS version 8.0 (SPSS, Chicago, IL, USA). The relationships between individual patient variables and rejection were characterized using stepwise logistic regression. Categorical patient variables included HLA-class I match (matched sibling vs serological match vs serological mismatched), prophylaxis for graft-versus-host disease (single agents vs combination), gender match between donor-recipient (matched vs male donor-female recipient vs female donormale recipient), prior chemotherapy (yes vs no), disease (cancer vs not cancer) and administration of ATG (yes vs no). Continuous patient variables included age, marrow cell dose per kg of actual body weight, busulfan steady-state concentration (C ss ) from doses 5 and 9, cyclophosphamide dose expressed relative to body weight (mg/kg) and cyclophosphamide dose expressed relative to body surface area (mg/m 2 ).
Results
Busulfan pharmacokinetics
The median busulfan clearance in younger children 0.25-4 years of age was 5.91 (range 2.80-29.10) ml/min/kg and 140 (range 88.3-598) ml/min/m 2 . In older children (5-16 years of age), the median (range) was 3.56 (1.65-12.18) ml/min/kg and 116 (59.5-310) ml/min/m 2 (P = 0.024 for ml/min/m 2 ). The median value for bias, calculated by subtracting day 5 from day 9 busulfan clearance and subsequently dividing by the day 5 clearance, was Ϫ2% (range Ϫ62% to +84%). The median value for precision, the absolute value of this ratio, was 19% (range 0.18-84%). The precision was less than 10% for 24 of the 53 (48%) patients. Twenty-three of 29 patients (79%) treated on protocols that specified adjustment of dose to achieve a desired busulfan C ss required dose adjustment based on pharmacokinetic analysis of the first dose.
Outcome of HSCT
The median day of the ANC nadir was 7, and the median day to engraftment as measured by the return of ANC to Ͼ0.5 ϫ 10 9 /l was 19 days. The median time for platelet count to rise above 50 ϫ 10 9 /l was 21 days. Graft rejection occurred in eight of the 53 (15%) patients, with four of the rejections occurring after day 80 (Table 4 ). These eight patients had the following diseases (n/disease): thalassemia (2), acute myeloid leukemia (AML, n = 1), hemophagocytic lymphohistiocytosis (1), myeloproliferative disorder (1), bare lymphocyte syndrome (1), myelodysplastic syndrome (1), and metachromatic leukodystrophy (1). Two of these eight patients who had rejected their grafts had received chemotherapy prior to receiving their preparative regimen (for AML and hemophagocytic lymphohistiocytosis).
On logistic regression analysis, busulfan C ss was the only statistically significant parameter associated with the observed probability of rejection in univariate model (P = 0.0024). (Busulfan C ss was the only variable associated with rejection (P = 0.0059) in subset analysis excluding the three children without busulfan clearance data after dose 5. Therefore, the results are presented for all children.) Other variables that were of borderline statistical significance, based on the criteria of P Ͻ 0.10 on univariate analysis, were also identified. Serological HLA-class I match (P = 0.0964) and the cyclophosphamide dose (mg/m 2 ) (P = 0.0703) were marginally related to graft rejection, while cell dose, graft-versus-host disease prophylaxis, cyclophosphamide dose (mg/kg), gender match between recipient and donor, age and ATG administration were unrelated to graft rejection (P Ͼ 0.1). Figure 1 shows the relationship between busulfan C ss and rejection (with 1 indicating rejection). The solid line represents the predicted probability of graft rejection in relation to busulfan C SS. At low busulfan C ss (Ͻ200 ng/ml) the predicted probability of rejection was 55%, whereas, at higher busulfan C ss (Ͼ600 ng/ml), the predicted probability of rejection was less than 12%. Graft rejection occurred in five of 20 patients with a busulfan C ss Ͻ600 ng/ml and in three of 33 patients with a busulfan C ss Ͼ600 ng/ml (Table 5) .
No relapses occurred in the 14 children transplanted for AML in first complete remission. The median busulfan C ss in these patients was 837 ng/ml (range 246-1371 ng/ml). Relapse occurred in one AML patient transplanted in refractory relapse, one in second complete remission and one with biphenotypic leukemia who had a busulfan C ss of 681, 719 and 720 ng/ml, respectively. The other two patients who relapsed were patients with acute lymphoblastic leukemia and one with chronic myelogenous leukemia.
Forty (75%) and nine (17%) patients experienced a maximum toxicity of grade 1 and 2, respectively, in any organ system. Four of the 53 (8%) patients experienced severe RRT (grade 3 or 4), three of whom experienced grade 4 hepatotoxicity. The relationship between RRT and individual patient variables could not be assessed by logistic regression analysis because of the limited number of severe RRT. One of the four patients with severe RRT had a busulfan C ss Ͼ900 ng/ml, the previously defined concentration associated with severe RRT in predominantly adolescent and adult populations. 15, 19, 20 However, 10 of the 53 patients (19%) had a busulfan C ss higher than 900 ng/ml. 15, 19, 20 Nine of the 10 patients with a C ss Ͼ900 ng/ml had no toxicity greater than grade 2 in various organ systems. 
Figure 1
The relationship between busulfan C ss and graft rejection in pediatric patients undergoing HSCT. The solid line represents the predicted probability of rejection in relation to busulfan C ss determined by univariate logistic regression (P = 0.0024).
Table 5
Incidence of graft rejection in relation to busulfan C ss and allogeneic graft source Number of rejections/Number of patients. b Class C data not available in two patients, both of whom had busulfan C ss Ͼ600 ng/ml.
Discussion
The major finding of this study was that busulfan C ss is a determinant of graft rejection in children undergoing HSCT following the BU/CY preparative regimen. We observed a decreasing risk of rejection with increasing busulfan C ss .
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The other variables examined did not appear to influence the probability of rejection; however, the analysis is limited because of the relatively low number of patients who experienced rejection (n = 8, Table 4 ). In these eight patients, the busulfan C ss ranged from 120 to 856 ng/ml. The graft source was HLA class I serologically matched unrelated (3), HLA class I serologically matched parent (2), matched sibling (2), and HLA class I serologically mismatched unrelated (1). Busulfan C ss was less than 300 ng/ml in the two patients who rejected grafts from a matched sibling donor. Of the remaining six patients experiencing rejection, five were transplanted from a serologically matched donor, and one received a graft from a class I serologically mismatched donor. There were 16 serologically matched donor-recipient pairs in which the class I allele data was pursued. However, lack of cells or DNA from donors or recipients precluded sequencing analysis in 15 of the 16 donor-recipient pairs, of which five experienced rejection. Hence, it is not known whether the five graft failure cases encoded undetected class I allele disparities that might have contributed to their risk of graft failure. 21 Future studies of graft failure in children conditioned with busulfan will require definition of the potential role of allele disparities.
The results from this analysis qualitatively agree with our earlier observations. 15 In a report from Bolinger et al, 18 a busulfan C ss Ͻ600 ng/ml was associated with graft rejection in 31 children with allogeneic grafts from various sources (25 HLA matched sibling; 4 HLA matched unrelated donor; 1 matched parent; 1 mismatched parent) receiving BU/CY Ϯ ATG. In addition, these investigators reported in abstract form that adjusting the busulfan dose to achieve a busulfan C ss of 600 to 900 ng/ml increased the rate of engraftment from 74% to 96% in 24 children. 24 In contrast, no relationship between busulfan C ss and graft rejection was observed in children with ␤-thalassemia receiving a graft from a genotypically HLA-matched sibling, even though six of 64 patients had busulfan C ss Ͻ200 ng/ml and 53 had busulfan C ss Ͻ600 ng/ml. 25 However, only five (7.5%) of the children experienced rejection, sug-gesting that these children received grafts better matched in minor histocompatability antigens than our patients or those in Bolinger et al's study.
The relationship between relapse in patients diagnosed with AML and individual patient variables, including busulfan C ss , could not be assessed using logistic regression because a limited number (3) of relapse events occurred. No relapses occurred in the 14 children transplanted for AML in first complete remission, who had a median busulfan C ss of 837 ng/ml. We have previously demonstrated that busulfan C ss Ͼ900 ng/ml has been associated with a decreased incidence of relapse in adults with chronic myelogenous leukemia (CML) receiving the BU/CY preparative regimen. 26 Baker et al 27 recently reported that relapse was not related to busulfan C ss in 52 patients with AML in first complete remission who received BU/CY followed by autologous (n = 25) or allogeneic (n = 27) grafts. Sixteen (31%) of the patients relapsed after an unspecified time to last follow-up. The low number of patients receiving grafts from one type of allograft may have limited this analysis, as exemplified by the regression analysis showing that graft source was not associated with the risk of relapse (relative risk = 2.7 with 95% confidence interval of 0.9-8.0; P = 0.08), which is in contrast to other reports in this patient population. 28 Severe RRT did not appear to be related to busulfan C ss in these children. The incidence of severe RRT increases as busulfan C ss exceeds 900 ng/ml in studies primarily involving adults receiving a BU/CY preparative regimen. 15, 19, 20 However, in adults with CML receiving BU/CY, elevated busulfan C ss does not increase the risk for severe RRT, possibly because of less intense chemotherapy in the period prior to HSCT. 26 Ten of 53 children in the present study achieved busulfan C ss Ͼ900 ng/ml, one of whom had severe RRT. Three children with C ss Ͻ900 ng/ml had grade 4 hepatotoxicity. Bolinger and coworkers 24 did not observe a relationship between busulfan C ss and RRT in 31 children receiving BU/CY Ϯ ATG, with a cyclophosphamide dose of 200 mg/kg. However, only one of the 31 patients studied had a busulfan C ss Ͼ900 ng/ml. These results lead to at least two hypotheses. Specifically, young age may protect from severe RRT or the higher doses of cyclophosphamide received by children may obscure any relationship between busulfan C ss and toxicity.
The majority (81%) of the children in this study received 200 mg/kg or more cyclophosphamide while only 19% received 120 mg/kg, the dose most often used in adults. Each of the three children who experienced grade 4 hepatotoxicity received at least 200 mg/kg of cyclophosphamide. Hepatic veno-occlusive disease has recently been related to the AUC of the acid metabolite of 4-hydroxycyclophosphamide in 105 adult CML patients receiving a bone marrow graft from an unrelated donor following a CY/TBI preparative regimen. 29 In co-cultures of hepatocytes and sinusoidal endothelial cells, acrolein, a toxin formed by ␤-elimination from aldophosphamide (a tautomer of 4-hydroxycyclophosphamide) is a hepatotoxin. 30 The suggestion that cyclophosphamide contributes to hepatotoxicity in HSCT is also suggested by the apparent lower incidence of VOD in patients receiving busulfan in combination with melphalan and thiotepa. 31 As doses of a second hepatotoxin (cyclophosphamide) increase and are varied within a study, one would expect the relationship between busulfan C ss and the incidence of VOD to become more difficult to detect.
In conclusion, busulfan C ss is a determinant of graft rejection in children receiving a BU/CY Ϯ ATG preparative regimen. Severe regimen-related toxicity to this preparative regimen does not appear to be related to busulfan C ss , in contrast to what has been observed in adults. Higher doses of cyclophosphamide in children may have obscured any relationship between busulfan C ss and RRT in children. It is likely that the outcome of HSCT in pediatric patients receiving the BU/CY regimen could be improved through optimization of busulfan C ss .
